Introduction
The DNA/RNA market is in its infancy with no significant products launched across the seven major
markets. Despite the unproven nature of the sector in terms of market potential, it is commanding
considerable interest across the biotechnology industry. Datamonitor has identified 99 companies
developing DNA/RNA therapies, with 229 products in development.
Scope of this report
- Benchmarking of the current and future DNA/RNA market, by technology and therapeutic focus, in
terms of number of projects and dollar value
- Analysis of market trends and future opportunities for both biotech and pharmaceutical players
- Investigation of the steps that the industrys emerging players are taking to increase
innovation in their businesses and improve strategic position
- Full profiles of 19 DNA/RNA programs set to launch by 2010, encompassing product development and
company strategy
Research and analysis highlights
The DNA/RNA market will not receive significant attention from the wider pharmaceutical industry
until a series of antisense, aptamer and gene therapies are launched and achieves significant uptake
across the seven major markets. The first product to achieve this is likely to be Eyetech/Pfizers
Macugen.
Oncology dominates the DNA/RNA market, both in terms of commercial potential and pipeline
development, while antisense and gene therapies lead the technological focus of those products set
to launch by 2010.
Key reasons to read this report
- Forecast how advances in science and changes in the commercial environment will offer new
opportunities to benefit from DNA/RNA therapies
- Identify key pipeline products for in-licensing opportunities as well as areas of unmet need
- Benchmark your position within the DNA/RNA market and identify the optimum strategy for future
success
View Cart
